Asensus Surgical announces the sale of the Senhance robotic system

The Senhance system will be placed in the hospital of the Commonwealth of Independent States

RESEARCH TRIANGLE PARK, North Carolina, Aug. 04, 2022 (GLOBE NEWSWIRE) — Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company digitizing the interface between surgeon and patient to usher in a new era of Performance-Guided Surgery™, today announced the sale of a Senhance® Surgical System to company’s distribution partner, and will be placed in a hospital in the Commonwealth of Independent States (CIS) region.

“We are thrilled to partner with another institution to launch a Senhance program to deliver better patient outcomes,” said Anthony Fernando, President and CEO of Asensus Surgical. “With the combination of unique instrumentation, including 3mm and articulation, advanced safety features such as haptic feedback, and the industry’s only intelligent artificial intelligence platform, Senhance offers the opportunity to revolutionize the capabilities of a surgical team when performing laparoscopic procedures.”

Leveraging the Performance-Guided Surgery™ framework, the Senhance Surgical System advances clinical intelligence by providing surgeons with augmented intelligence and digital tools to perform consistently superior surgery.

Asensus Surgical’s technology platform, Senhance Surgical System, is the first-of-its-kind digital laparoscopic platform that leverages augmented intelligence to deliver unparalleled performance and patient outcomes through machine learning. Senhance goes beyond typical surgical robotic systems, providing surgical assurance through haptic feedback, eye tracking camera control and 3D visualization, and is the first platform to offer 3mm instruments ( the world’s smallest instrument available on a robotic surgical platform). The Senhance Surgical System is powered by the Intelligent Surgical Unit™ (ISU™). The ISU provides artificial vision camera control for a surgeon by responding to commands and recognizing certain objects and locations within the surgical field, and allows a surgeon to alter the visualized field of view using the movement of their instruments .

About Asensus Surgical, Inc.

Asensus Surgical, Inc. is digitizing the interface between surgeon and patient to usher in a new era of performance-driven surgery by unleashing clinical intelligence for surgeons to achieve consistently superior results and a new standard of surgery. This builds on the foundation of digital laparoscopy with the Senhance surgical system powered by Intelligent Surgical Unit (ISU) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive, and economic gaps that determine surgical outcomes and value-based healthcare. Learn more about performance-guided surgery and digital laparoscopy with the Senhance Surgical System here: www.senhance.com. Now available for sale in the US, EU, Japan, Russia and some other countries. For a complete list of indications for use, visit: www.senhance.com/indications. For more information, visit www.asensus.com.

Follow Asensus

Email Alerts: https://ir.asensus.com/email-alerts
LinkedIn: https://www.linkedin.com/company/asensus-surgical-inc
Twitter: https://twitter.com/AsensusSurgical
Youtube: https://www.youtube.com/c/transenterix
Vimeo: https://vimeo.com/asxc

Forward-looking statements

This press release includes statements relating to the Senhance Surgical System and the sale of a Senhance System to a distribution partner, which will ultimately be placed in an end user hospital in the Commonwealth of Independent States. These and other statements regarding our future plans and objectives constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor of liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties which are often difficult to predict, are beyond our control and which could cause results to differ materially from expectations and include whether the Senhance Surgical System provides the ability to revolutionize the capabilities of a surgical team when performing laparoscopic procedures. For a discussion of the risks and uncertainties associated with the Company’s business, please see our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on February 28, 2022 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

INVESTOR CONTACT:
Mark Klausner or Mike Vallie
443-213-0499

[email protected]

MEDIA CONTACT:
Lauren Stredler
847-271-6891
CG Life

[email protected]

A photo accompanying this ad is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/24cd4ee5-138f-47e8-b0b0-fd04ebb2844e



main logo

Senhance Surgical System Performance Guided Surgery™

Leveraging the Performance-Guided Surgery™ framework, the Senhance Surgical System advances clinical intelligence by providing surgeons with augmented intelligence and digital tools to perform consistently superior surgery.

Comments are closed.